Cryoneurolysis for Improvements in Pain, ADL and QOL in Patients With Ankle Osteoarthritis

Cryoneurolysis for Improvements in Pain, Activities of Daily Living and Quality of Life in Patients With Ankle Osteoarthritis

This will be an open-label trial to describe the effects of cryoneurolysis with iovera° on symptom relief in patients with painful Kellgren-Lawrence (KL) grade 2-4 ankle osteoarthritis (OA). The Foot and Ankle Outcome Score (FAOS) subscales will be used to assess outcomes at 6, 12 and 24 weeks after treatment.

The aim of this study is to assess clinically significant long-term symptomatic relief with cryoneurolysis in people with unilateral ankle osteoarthritis (OA). The investigators will treat 1) the Superficial Fibular Nerve (SFN), Sural Nerve (SN) and Saphenous Nerve and/or 2) the Deep Fibular Nerve (DFN) with cryoneurolysis using the iovera° device. The primary study endpoint, clinically significant improvement in pain 12 weeks after each treatment, will be assessed using the FAOS pain subscale. If a participant is a non-responder (<20% improvement in pain within the 12 weeks following baseline), then the other treatment will be offered (e.g. if start with superficial group, then offer the DFN).

The secondary outcomes will be improvement in quality of life (FAOS-QoL), activities of daily living (FAOS-ADL) and Numerical Rating Scale (NRS) for pain.

The tertiary outcome will be improvement in physical performance measures (40m fast-paced walking test, standing balance test).

Inclusion Criteria:

• Participation in an institutional review board-approved informed consent process, culminating in providing written consent.
• Willingness and ability to comply with the study procedures, visit schedules and ability to follow verbal and written instructions.
• Male or female over 18 years of age.
• Currently Kellgren-Lawrence (KL) Grade 2, 3 or 4 in the ankle based on X-ray (weight-bearing mortise views with 20° internal rotation) or weight-bearing CT scan of the ankles.
• Limited by unilateral ankle pain, rated on a Numerical Rating Scale for pain severity as ≥5 on most days over the last month.
• Foot and ankle outcome score (FAOS) of < 75 in at least 1 category.
• Body mass index (BMI) ≤ 50 kg/m2
• Ambulatory
• Willingness to abstain from the use of protocol-restricted medications during the study and also willing to abstain from use of analgesics other than acetaminophen 1 week prior to beginning of the study.
• Has undergone at least one prior conservative osteoarthritis treatment (e.g. physical therapy, analgesics).

Exclusion Criteria:

• Baseline knee, hip, spine or other limitations that affect walking ability to a greater extent than the ankle.
• Cryoglobulinemia, paroxysmal cold hemoglobinuria, Raynaud's disease, cold urticaria.
• Clinical signs or symptoms of active or recurrent infection in the index ankle joint or overlying skin.
• Intra-articular, intravenous or intramuscular corticosteroid (investigational or marketed) within 3 months of screening
• Oral corticosteroids (investigational or marketed) within 2 weeks of screening (unless on a chronic stable dose for ≥3 months prior to enrollment).
• Women who are pregnant (due to potential for the change in body mass and distribution to alter ankle symptoms over the period of follow-up).
• Any condition other than OA of the ankle joint which, in the opinion of the investigators, affects their ability to ambulate to a sufficient degree to interfere with the assessment of the safety and treatment effects of the study injection.
• Arthroscopy or open surgery of the ankle joint within 6 months of screening.
• Planned/anticipated surgery of the index ankle joint during the 6-month study period.
• Any clinically significant degree of cognitive impairment or other condition, finding, or psychiatric illness at screening which, in the opinion of the investigator, could compromise patient safety or interfere with the assessment of the safety and treatment effects of the study injection.
• Skin breakdown at the ankle joint where the injection is planned to take place.
• Participated in any investigational drug or device trial within 30 days prior to screening or concurrent participation in another research study that could complicate interpretation of the findings of either study.
• Current consumption of more than 14 alcoholic drinks per week.
• Patients with diffuse pain conditions (Complex pain - diffuse or confounding pain, fibromyalgia, etc.).
• Known altered nerve anatomy or physiology (e.g. neuropathy) at the target, such as due to a congenital, traumatic or surgical cause.